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Human papillomavirus (HPV) has been implicated as
the primary etiologic agent of cervical cancer. Potential vac-
cines against high-risk HPV types are in clinical trials. We
evaluated vaccination programs with a vaccine against
HPV-16 and HPV-18. We developed disease transmission
models that estimated HPV prevalence and infection rates
for the population overall, by age group, by level of sexual
activity within each age group, and by sex. Data were
based on clinical trials and published and unpublished
sources. An HPV-16/18 vaccine for 12-year-old girls would
reduce cohort cervical cancer cases by 61.8%, with a cost-
effectiveness ratio of $14,583 per quality-adjusted life year
(QALY). Including male participants in a vaccine rollout
would further reduce cervical cancer cases by 2.2% at an
incremental cost-effectiveness ratio of $442,039/QALY
compared to female-only vaccination. Vaccination against
HPV-16 and HPV-18 can be cost-effective, although includ-
ing male participants in a vaccination program is generally
not cost-effective, compared to female-only vaccination.
W
ith 370,000 cases per year and a death rate of
approximately 50%, cervical cancer is the third most
common malignancy in women worldwide (1,2).
Epidemiologic and laboratory evidence has implicated cer-
tain types of human papillomavirus (HPV) as the etiologic
agents of cervical cancer (3,4). On the basis of this evi-
dence, effort is under way to develop an HPV vaccine that
targets these oncogenic HPV types (5).
Clinical trials of preliminary vaccines in humans began
in the late 1990s (6). Recent data from an ongoing phase II
trial (7) look very positive, demonstrating that an HPV-16
vaccine can prevent HPV infection and precancerous
lesions in vaccinated women. These data provide hope that
an HPV vaccine may be a reality within 5 to 10 years.
Public health officials will then need to make important
decisions regarding who and when to vaccinate and what
level of vaccine penetration is necessary to substantially
reduce disease prevalence.
Central to this discussion is the question of whether
both sexes should be vaccinated. The general assumption
in the literature is that men and boys should be vaccinated
(5,6,8,9). Although long-term sequelae of HPV infection
for men is on average less serious (particularly for hetero-
sexual men), men act as vectors for infection. Including
men and boys in a vaccine program would enhance herd
immunity and decrease overall incidence of cervical can-
cer. In this article, we evaluate the benefit and cost-effec-
tiveness of adopting a vaccination strategy for both sexes,
compared with that of adopting a female-only strategy. The
incremental cost-effectiveness of a vaccination rollout
strategy is calculated by dividing the difference in costs
between strategies by the difference in quality-adjusted life
expectancy. 
Because results of the long-term phase III/IV trial are
not available, the efficacy of the HPV vaccine is still
unknown. Also, acceptance of an HPV vaccine is likely to
vary substantially. Resistance to a vaccine may arise
because HPV is a sexually transmitted disease (6,10),
although recent studies suggest that an HPV vaccine may
be reasonably well accepted (11). We therefore evaluated a
wide range of vaccine efficacies and population penetra-
tions to understand what is required for a female-only pro-
gram to achieve sizeable benefit and to identify the
scenarios in which incremental male vaccination makes
most sense. 
Methods
To capture the effect of a male vaccination program on
female HPV infection rates and cervical cancer incidence,
we needed to directly model the effect of vaccination on
HPV disease transmission dynamics. Therefore, we devel-
oped disease-transmission models for HPV-16 and HPV-
18, the types associated with most cervical cancer cases
and the most likely to be included in HPV vaccines (3,6).
For both types, the transmission models estimated HPV
prevalence and infection rates for the U.S. population
overall, by age group, level of sexual activity, and sex.
The models also enabled us to evaluate the effect of
Evaluating Human Papillomavirus
Vaccination Programs
Al V. Taira,* Christopher P. Neukermans,† and Gillian D. Sanders†‡
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 11, November 2004 1915
*Stanford School of Medicine, Stanford, California, USA; †Stanford
University, Stanford, California, USA; and ‡Duke University,
Durham, North Carolina, USAvarious vaccination programs on prevalence and infection
rates.
Long-term equilibrium infection rates by age group, by
level of sexual activity, and by sex for each vaccination
scenario were determined in the transmission model.
These infection rates were then incorporated into a proba-
bilistic decision model. This model estimated the annual
incidence of HPV-related precancerous lesions, lifetime
cases of invasive cervical cancer, resulting cervical cancer
deaths, and total cost of care for a given set of age-specif-
ic infection rates. By using the combination of the trans-
mission and decision model, we estimated the
effectiveness and cost-effectiveness of alternative vaccine
rollout strategies.
Transmission Model Structure 
We used Stella software (v7.0.3, High Performance
Systems, Hanover, NH) to develop deterministic transmis-
sion models for heterosexual transmission of HPV types
16 and 18. Because level of sexual activity and HPV
prevalence are highly age-dependent, we divided the pop-
ulation into nine age categories, from age 12 to age 50. We
further divided each age category into four subcategories
based on level of sexual activity (Table 1). HPV preva-
lence among their pool of sex partners, infectivity per
infected partner, HPV shedding duration, and HPV infec-
tion rates were estimated for each age and activity group to
develop a natural history transmission model. Vaccine pen-
etration and efficacy were added to evaluate the effect of
potential vaccine programs.
In our analysis, persons of both sexes were either HPV
infected or uninfected at the beginning of each time peri-
od. In each period, uninfected persons could remain unin-
fected or become infected, on the basis of infection rates
by age category (Figure 1). Infection rates were deter-
mined by number of sex partners, HPV prevalence among
pool of sex partners, and infectivity per infected partner.
HPV prevalence among the pool of sex partners was a
function of HPV prevalence by age and risk group, and by
sexual mixing patterns (preference of partners in different
age groups for partners in different sexual classes) between
age groups and between high- and low-risk sexual activity
groups (Table 1). Details regarding the transmission model
can be found in the online Appendix (http://www.cdc.gov/
ncidod/EID/vol10no11/04-0222_app.htm).
Transmission Model Data
Sex Partnering 
The level of sexual activity and mixing patterns
between subgroups can affect the transmission dynamics
of a sexually transmitted disease (23,24). Table 1 shows
our estimates for these variables, based on a survey of the
published literature. On average, the number of new sex
partners per year for a person in our cohort increases from
onset of sexual activity to age 24 and then decreases
through age 50 (12–14). Mixing between sexual activity
groups was assumed to be assortive, with a moderate pref-
erence to select partners in similar sexual activity groups
(22). Mixing between age groups was predominantly older
men with younger women (12–14). 
Duration of HPV Shedding 
Persons infected with HPV in a given period are
assumed initially to be actively shedding virus and there-
fore contagious. In subsequent periods, infections can
completely resolve or become dormant. Persons whose
infections resolve before precancerous lesions develop are
assumed to be at no risk for HPV-related cervical cancers,
unless they become reinfected with the virus. Persons for
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longer transmit the virus, but they remain at increased risk
for precancerous lesions and cancer in the future (Table 1). 
Infectivity per Infected Partner
By using our estimates of HPVprevalence among pools
of sex partners, numbers of new sex partners, sexual mix-
ing patterns, and duration of HPV shedding, we derived
estimates for infectivity per infected partner for persons of
both sexes in each age group in the absence of a vaccina-
tion program. Infectivity was highest for women and men
<18 years, at ≈0.35 infections per infected partner. This
number dropped gradually for older age categories (to
≈0.15 infections per infected partner), representing
increased resistance to infection and possible changes in
sexual activity and practices in these age groups.
HPV Vaccine Characteristics
We assumed that the HPV vaccine would initially be
administered by a series of three injections to 12-year-old
girls. In our base-case analysis, booster shots would be
required for persons in their early 20s. In this scenario, the
protective effect of the vaccine lasts for 10 years after the
most recent booster. We assumed that the vaccine had 90%
efficacy against both HPV-16 and HPV-18 and was given
to girls at age 12, with a booster at 22. We assumed 70% of
girls were vaccinated, with a vaccine cost of $300 for the
initial vaccination (three doses) and $100 for the booster.
Decision Model Structure and Assumptions
In a previous analysis (25), we modeled the overall pro-
gression of high-risk oncogenic HPV types to different
stages of cervical dysplasia and cancer. In our current
analysis, we adapted this model to evaluate the natural his-
tory and vaccination scenarios regarding HPV-16 and
HPV-18. Estimates regarding Pap screening, lesion treat-
ment, cancer progression and survival, costs, and utilities
are based upon our previous analysis (25). Specific pro-
gression rate of HPV-16 and HPV-18 to different stages of
cervical dysplasia and cancer were estimated from the lit-
erature (15,19,20,26,27).
Model Validation 
To validate the model, we compared the incidence of
cervical cancer cases and deaths predicted by the prevacci-
nation natural history arm of our model with those report-
ed in the Surveillance, Epidemiology, and End Results
(SEER) registry (28). Our model’s annual rates of cervical
cancer cases and deaths matched 2001 SEER estimates
within 10%. The predicted age-specific prevalence of HPV
infection in our natural history arm also has a shape and
peak of similar magnitude to that reported in the literature
(15–18).
Results
Base-Case Analysis
Under our base-case scenario, vaccinated girls would
experience a 61.8% overall reduction in acquiring cervical
cancers over a lifetime. The analysis predicted, given the
current U.S. population of 12-year-old girls (approximate-
ly 2.0 million), that the number of expected lifetime cases
of cervical cancer related to HPV-16 or HPV-18 would
drop from 9,147 to 422, a 95.4% reduction. This strategy
would add an average of 6.1 quality-adjusted days of life
per woman and have a cost-effectiveness ratio of $14,583
per quality-adjusted life-year (QALY) gained compared to
the current environment (Table 2).
Vaccinating Men and Boys
If both sexes were vaccinated with an HPV-16/18 vac-
cine, total cervical cancer cases in that cohort would drop
by 63.9%, compared to the number of cases in the scenario
before vaccination. The number of cancer cases related to
HPV-16 or HPV-18 would decrease from a prevaccination
9,147 to 113, a 98.8% drop from the number in the pre-
vaccination scenario. Expanding the vaccination program
to men and boys would add an incremental 0.21 quality-
adjusted days of life per woman at a cost-effectiveness
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Figure 1. Schematic of the transmission model. The model is divid-
ed into nine age categories, with four subcategories per age group
(not shown) based on different levels of sexual activity. In each
period, uninfected persons can become infected. Infection rates
are based on number of sexual partners per year, infectivity per
infected partner, and percentage of potential partners who are
infected. These variables are age- and risk-group specific.
Infection rates for vaccinated persons also depend on the esti-
mated vaccine efficacy. Percentage of potential partners infected
includes partners within an age group and potential partners from
younger and older age groups. Estimated mixing patterns between
age groups differ by sex and age category.ratio of $442,039/QALY compared to the female-only
strategy (Table 2). 
Vaccine Penetration and Efficacy
Figure 2A shows how varying the vaccine coverage of
a female-only HPV-16/18 vaccination program affects the
number of lifetime cervical cancer cases. As expected, as
vaccine coverage increases, the number of cervical cancer
cases decreases. However, based on scenarios that used
our transmission model, the relationship is not linear.
Because of the benefits of herd immunity, vaccinating
even a relatively small portion of the target population
leads to substantial decreases in disease prevalence and
resulting negative sequelae relative to prevaccination rates.
Figure 2A also illustrates the effect of vaccinating both
sexes. A combined male-female program always results in
lower levels of cohort cervical cancer cases than a female-
only program. However, this difference is only large when
levels of female vaccine penetration are low.
Figure 2B shows the cost-effectiveness of HPV-16/18
vaccination programs compared to the current environ-
ment as coverage varies. The cost-effectiveness of female-
only vaccination is attractive at all ranges of vaccine
penetration. At lower vaccine penetration levels, including
male participants in the vaccination program also becomes
cost-effective. For example, at 30% female vaccine pene-
tration, including male participants is reasonably cost-
effective at $40,865/QALY compared to vaccinating
female participants only. Figures 2C and 2D show similar
data for changes in vaccine efficacy.
Vaccination Age
Our analysis assumes that vaccination would focus on
children 12 years of age. We considered alternative vacci-
nation strategies that would focus on either infants or per-
sons 18 years of age. Because most women are not
sexually active until after age 12, focusing on infants or
12-year-old children leads to approximately the same
decrease in lifetime cases of cervical cancer. However,
delaying initial vaccination until age 18 leads to only a
54.7% decrease in the number of cancer cases in this
cohort. If focusing on the older age group also leads to a
decrease in vaccine penetration (60%), then program
effectiveness drops further to a 50.9% decrease in lifetime
cervical cancer cases in this cohort.
We also considered how the optimal vaccination age
was affected if the efficacy of the vaccine waned. If the
vaccine efficacy waned over 10 years and no booster was
provided, a vaccination program that targeted 18-year-old
women would dominate one which targeted 12-year-old
girls. In this scenario the cost-effectiveness of also vacci-
nating 18-year-old men would be economically favorable,
with a cost-effectiveness of $57,795/QALY compared to
the cost-effectiveness of vaccinating women only. If, how-
ever, two booster shots were given at 5-year intervals to
maintain the vaccine’s efficacy, 12-year-old girls would
return to being the optimal vaccination group, but the cost-
effectiveness of vaccinating boys would increase to
$388,368/QALY.
Effect of Vaccination over Time 
and Catch-up Vaccination
Under our base-case scenario with an HPV-16/18 vac-
cine, the first cohort of vaccinated 12-year-old girls would
experience a 29.7% decrease in overall cervical cancer
cases at a cost-effectiveness of $27,566/QALY, compared
to their experience without vaccination. Vaccinating boys
would cost $285,776/QALY compared with a female-only
program to reduce cervical cancer cases an additional
4.7%. In time, however, lifetime cervical cancer cases
would reach a steady-state of ≈62% of prevaccination
level. Thus, even the first cohort would experience almost
half of the achievable benefit of a long-term vaccination
program. Table 3 displays the average reduction in lifetime
cervical cancer risk for girls vaccinated at age 12 through
a large-scale vaccination program, compared to the
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catch-up vaccination once a vaccine becomes available.
Pap Screening Guidelines
Although an HPV-16/18 vaccine would not protect
against all oncogenic HPV strains, we wanted to explore
whether the vaccine could sufficiently reduce the preva-
lence of cervical cancer and precancerous lesions to allow
for less frequent cervical cancer screening. Our base-case
analysis assumes that 71% of women get Pap smears every
2 years (29). Figure 3 presents the cost-effectiveness of
moving to more or less frequent screening intervals, in the
presence of an established vaccine program.
Sensitivity Analyses
We performed sensitivity analyses on a range of model
variables. The female-only vaccination program remained
economically attractive under a wide range of variable
assumptions. However, the incremental benefit of vacci-
nating men and boys was sensitive to changes in key vari-
ables. Figure 4 shows one-way sensitivity analyses of the
cost-effectiveness of incrementally vaccinating male
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Figure 2. A) Vaccine penetration scenario. Relationship between percentage of the population receiving the vaccine and the number of life-
time cervical cancer cases. The solid line represents a female-only vaccination strategy. The dashed line represents a strategy of vacci-
nating both sexes. The arrow indicates the base-case scenario of a female-only strategy with 70% penetration. B) Vaccine penetration
scenario. Relationship between percentage of the population receiving the vaccine and program cost-effectiveness. The solid line repre-
sents the cost-effectiveness ($/quality-adjusted life-year [QALY]) of a female-only vaccination program compared to current practice. The
dashed line represents the incremental cost-effectiveness of including male participants in a vaccine program compared to a female-only
strategy. The arrow indicates the base-case scenario of a female-only program with 70% penetration. C) Vaccine efficacy scenario.
Relationship between vaccine efficacy and the number of cohort lifetime cervical cancer cases. The solid line represents a female-only vac-
cination strategy. The dashed line represents a strategy of vaccinating both sexes. The arrow indicates the base-case scenario of a female-
only strategy assuming 90% vaccine efficacy. D) Vaccine efficacy scenario. Relationship between vaccine efficacy and program
cost-effectiveness. The solid line represents the cost-effectiveness ($/QALY) of a female-only vaccination program compared to current
practice. The dashed line represents the incremental cost-effectiveness of including male participants in a vaccine program compared to a
female-only strategy. The arrow indicates the base-case scenario of a female-only program at 90% vaccine efficacy.participants compared to the cost-effectiveness of female-
only vaccination. 
Discussion
By using a disease transmission model for the sexual
transmission of HPV, we demonstrated that an HPV-16/18
vaccine would be cost-effective and could reduce lifetime
cervical cancer cases by 61.8%. Although a universal vac-
cination program would have the greatest benefit, because
of the benefits of herd immunity, a program that achieves
even 70% coverage would dramatically reduce cohort life-
time cervical cancer cases. 
Although the literature often suggests that men and
boys should be included in an HPV vaccination program
(5,6,8,9), our results suggest that this strategy may not be
the most cost-effective public health strategy. Under our
base-case assumptions, including men and boys in a vacci-
nation program would further reduce infections and cancer
cases only slightly, with an unattractive cost-effectiveness
ratio of $442,039/QALY saved. In addition, the absolute
cost of expanding coverage to men and boys is high.
Assuming a $300 vaccine, achieving 50%–70% coverage
for the current U.S. population of approximately 2.1 mil-
lion 12-year-old boys would cost >$300 million annually. 
In certain scenarios, such as those in which vaccine
efficacy wanes rapidly without boosters or overall vaccine
coverage is low, vaccinating male participants can have a
substantial effect (Figure 4). In a recent article that mod-
eled risk groups but not age groups, Hughes et al. (30)
found that for a single-type HPV vaccine with a 10-year
mean duration and no booster that was meant for 16-year-
olds, a program focusing on girls would have only two
thirds of the impact on HPV infection rates as a program
focusing on both sexes. Modeling both risk and age
groups, we found that the incremental cost-effectiveness
ratio of vaccinating boys dropped to $51,646/QALY for a
vaccine with rapidly waning efficacy and no booster. Also,
if vaccination rates are lower among the most sexually
active girls, the female-only vaccination strategy will be
less effective. In sensitivity analyses, we demonstrated that
vaccinating boys in such a situation would be reasonably
cost-effective. For example, if vaccine penetration
amongst the highest risk girls reached only 30%, the cost-
effectiveness ratio of vaccinating boys drops from
$442,039/QALY to $116,413/QALY. Nonetheless, even in
this scenario, vaccinating boys is less cost-effective than
achieving higher vaccine penetration in girls at high risk
(analysis not shown).
We demonstrated that vaccinating women at the onset
of sexual activity is cost-effective and will lead to the
greatest reduction in cervical cancer incidence. Because
we assume that the vaccine will require a booster after
10 years, focusing on 12-year-olds would be more cost-
effective than focusing on infants ($27,600/QALY). If a
vaccination program focusing on infants were more wide-
ly accepted, with initial coverage of 80% versus 70% in
the base-case scenario, we would expect only an addition-
al 1.2% decrease in overall lifetime incidence of cervical
cancer, and the cost-effectiveness ratio would increase to
$28,181/QALY. Focusing on 18-year-olds would limit the
efficacy of the vaccine program and is not recommended
unless focusing on younger groups is not possible. 
We explored the effect of changing cervical cancer
screening interval guidelines once a vaccine program was
established (Figure 3). Even in a prevaccination environ-
ment, researchers found that moving from screening every
2 years to every year is not particularly cost-effective (31).
Kulasingam and Myers recently found that Pap testing
may be delayed to a later age than currently recommended
when an HPV vaccine has been given; although that analy-
sis did not include disease-transmission dynamics and
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Figure 3. Effect of changing frequency with which vaccinated
women receive a Pap test. The diamonds represent Pap testing
annually, every 2 years (base case), every 3 years, and every 4
years. The x-axis represents the lifetime expected cost of the vac-
cination strategy; the y-axis is the quality-adjusted life expectancy
in years. The incremental cost-effectiveness of increasing the fre-
quency of Pap testing for vaccinated women is indicated numeri-
cally above the cost-effectiveness frontier. QALY, quality-adjusted
life-year.predicted that broad-based immunization would decrease
cervical cancer incidence by 17% (32). By using a disease-
transmission model that predicts greater vaccine impact,
we demonstrated that Pap testing vaccinated women every
3 or 4 years had a more powerful effect than a no-vaccine
strategy (i.e., cost less and increased quality-adjusted life
expectancy). With a vaccine program in place, moving
from screening every 3 years to every 2 years cost
>$100,000/QALY, while annual screening is not economi-
cally favorable (Figure 3). Given these data, with a vaccine
program in place, physicians may be comfortable moving
to less frequent screening.
We did not include in our analysis the effect of an HPV
vaccine on several other cancers associated with HPV. We
also did not examine the effect of vaccines targeting the
nononcogenic HPV types most commonly associated with
genital warts. Including the former would make the vac-
cine strategies appear to be even more cost-effective. The
latter can be considered as a separate analysis, since a vac-
cine would offer little cross-protection between HPV types
(5). Also, although some have suggested that lesion treat-
ment protects against sequelae of future HPV infections
(e.g., squamous intraepithelial lesions and cervical cancer)
(30), we are not aware of evidence that supports this
hypothesis, so we did not include it in our analysis.
Including this potential benefit would diminish the cost-
effectiveness of a future vaccine. Finally, our analysis does
not examine targeted vaccination in men who are at high
risk, for instance, in the community of men who have sex
with men, in which HPV infection rates are higher than for
the general population.
Although this analysis modeled vaccine programs in
the United States, our results may have relevance for deci-
sion makers in less developed countries where public
health resources are limited and cervical cancer death rates
can be markedly higher than in the United States. These
countries may have difficulty achieving high levels of vac-
cine penetration. However, because even modest vaccine
coverage appears to substantially reduce cervical cancer
cases, a partial vaccination program that includes specific
populations might be more efficacious and cost-effective
for these countries than alternative options, such as Pap or
HPV screening.
Our analysis indicates that vaccinating 12-year-old girls
with an HPV-16/18 vaccine would cost $14,583 /QALY,
whereas vaccinating boys costs $442,039/QALY. In com-
parison, screening strategies of women for cervical cancer
with Pap smears has been estimated to cost between
$7,777 per life-year (LY) (quadrennial screening) and
$166,000/LY (annual screening) and depends on the type
of testing and prevalence of disease (31). Similarly, studies
of hepatitis B vaccines have estimated costs from $4,800
to $16,000/QALY to selectively vaccinate at-risk popula-
tions versus universal infant vaccination or versus no vac-
cination, respectively (33).
Vaccine evaluations that do not include disease trans-
mission can underestimate actual vaccine benefit (34–36).
By modeling disease transmission by age category and risk
grouping, we were able to estimate the effect of herd
immunity, which we know from actual vaccine rollouts
can be substantial (37,38). Prior cost-effectiveness analy-
ses of potential HPV vaccines by our group (25) and oth-
ers (32,39) have not included transmission by age
category, multiple sexual activity subgroups, or the protec-
tive benefit of herd immunity. As a result, these analyses
have likely underestimated the benefits of vaccination. In
addition, previous approaches did not attempt to evaluate
the cost-effectiveness of male vaccination. By modeling
transmission by different age and risk groups, we also were
able to address the issue of unequal vaccine penetration in
high-risk groups, an important real world phenomenon.
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Figure 4. Tornado diagram representing the incremental cost-
effectiveness ratios of one-way sensitivity analysis on vaccinating
men and women compared to vaccinating women only. The verti-
cal line represents the incremental cost-effectiveness ratio under
base-case conditions. The sensitivity analysis range is displayed
in parentheses next to each variable. Unequal penetration repre-
sents potential for lower (or higher) vaccine penetration in the
highest risk groups, from 30% to 80% of target group, compared
to 70% penetration in base case. QALY, quality-adjusted life-year.Because an HPV vaccine is likely to be available in the
future, public health officials will need to decide on HPV
vaccine rollout strategies. Our analysis shows that a vac-
cine that protects against HPV-16/18 could be cost-effec-
tive and has the potential to substantially reduce cervical
cancer rates. Additionally, under most scenarios, we
showed that including men and boys in a vaccination pro-
gram has a limited effect, which suggests that scarce
healthcare resources could be used in a more productive
manner. As ongoing clinical trials and vaccine develop-
ment progress, we believe our analysis will provide public
health officials with the tools needed to make optimal rec-
ommendations with limited resources. 
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